Day 2 – Thursday 12th September - EST/EDT (Eastern Daylight, GMT-4)
- Nadia Konneh - Senior Conference Director, Healthtech Lead, LSX
Technologies like artificial intelligence (AI) and machine learning are now shaping the future of the life sciences industry – and data is the foundation that drives these technologies forward. However, without the right tools to help manage and process it, the best data in the world can quickly become useless.
- As the entire industry evolves to embrace patient data, what are healthcare stakeholders getting right? What are they getting wrong?
- What are the biggest challenges to centralizing, standardizing, and managing data? How are you tackling those challenges?
- What do you see as the next frontier when it comes to data-driven solutions? What are the tools being developed right now that will transform the way we approach healthcare?
- What role does AI play in your company’s operations? Where do you see the most potential for healthcare to benefit from the current AI tide?
- Shruthi Bharadwaj - Global Lead, R&D Insights & Analytics, Sanofi
- Amit Garg - CEO, HiLabs
- Andrei Georgescu - CEO, Vivodyne
- Jayne Bower - Industry Executive Advisor, SAP
- Russell DeLapp - Industry Solutions Principal, Life Sciences, NTT DATA
- Building enhanced RWE capabilities to maximize data generation
- Harnessing data sources with the use of novel technologies
- Key considerations for RWE strategy to demonstrate value to regulators
- Navigating the RWE regulatory landscape to gain market access on a global scale
- Enhancing clinical trials and meet unmet patient needs
- Wendy Turenne - SVP, Real World Data & Operations, Aetion
- Joris Van Dam - VP Data Innovation, Exact Sciences
- Brian Clancy - RWD/RWE Partnerships Lead, Foundation Medicine
- Sherry Xiao - Senior Director, Integrated Evidence Generation, Pfizer
- Rebecca Miksad - Chief Medical Officer, Color Health
We have all the tools to make healthcare fairer and more equitable, but is it being deployed properly? Are we leveraging these tools? Is politics getting in the way?
- The promise of healthtech to improve health equity and access to care
- What technology is required to increase health equity in communities across the nation?
- Has commercial scalability caught up with equitable innovations?
- What are the missing tools in the toolkit?
- Pushing past the politics and making health equity a reality – What is the best way to do this?
- Michael Pace - CEO & Co-Founder, PalmHealthCo
- Willie Reaves - Head of Public Engagement, Cellino
- Keely Benson - Director, Massachusetts eHealth Institute, MassTech
- Arianne Kidder - Partner, Seae Ventures
- Dora Green - Director, US Health Equity, Takeda
- Investor perspective- building a thriving ecosystem that combines startups from all three verticals
- Going beyond ‘AI in drug discovery’ and bridging the gap between Healthtech & Biopharma
- Discussing how the integration of digital and medical technologies is enhancing diagnostics and monitoring
- Data – How is the industry leveraging all the patient data whilst addressing privacy concerns?
- Real-world examples of personalized care facilitated by this convergence
- Jim Parshall - Executive Director, Delivery Device R&D, Eli Lilly
- Paul Geevarghese - Co-Founder & COO, 9amHealth
- Chris Leggett - Senior Director & Head of Market Transformation, Vertex Pharmaceuticals
- Jeff Chu - Managing Partner, Features Capital
- Naomi Fried - CEO & Founder, PharmStars
- Oliver Barnes - US Pharmaceutical & Biotech Correspondent, The Financial Times
- Understanding what CVCs are looking for in when looking to invest in digital health & MedTech innovators
- What factors are driving your investment decisions, and which areas are primed for growth?
- Striking the right balance - aligning strategic and financial interests
- Analysis of the current valuation environment for digital health and MedTech startups
- Carrie Williams - VP & Partner, McKesson Ventures
- Suzie Yoon - Investment Principal, Takeda Digital Ventures
- Alex de Winter - VP New Ventures, Danaher Ventures
- John Pavletic - Executive Director, Lilly Ventures
- Vijay Kori - Head of Strategic Finance, Redesign Health
- Joe Heanue - CEO, Triple Ring Technologies
The outcome of the 2024 Presidential Election in the United States has the potential to significantly impact the healthcare and life sciences sector, shaping policies, regulations, and funding priorities for years to come. With broader issues such as healthcare accessibility, affordability, and innovation, the decisions made by the incoming administration will have far-reaching consequences for stakeholders across the industry. This panel discussion seeks to explore the potential implications of the election outcome on the healthcare and life sciences sector, examining key areas of impact and identifying strategies for navigating the evolving landscape.
- Potential impact on drug pricing, approval and insurance
- For medical devices, will stricter regulations create a fallout akin to the MDR in Europe?
- Impact of cyber-security and AI legislation on digital health innovation and implementation
The healthcare industry continues to be a hotbed of innovation and investment, with a diverse range of players contributing to its vibrancy. What future trends are on the horizon and how can the industry continue to move forward as a cohesive sector, play to each other’s strengths, and ensure we move into 2025 informed and continue to bring proactive and preventative treatments to patients.
- Understanding the patient – how will people manage their own health risks in 2025?
- Has AI delivered for healthcare in 2024?
- What can help partnerships to thrive?
- What future trends can we expect to see and what are the trends we can expect to forget?